SCHEDULE: FMR LLC Discloses Stake in Arrowhead Pharmaceuticals

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 5.2% in Arrowhead Pharmaceuticals Inc. as of March 31, 2026.

Summary

• FMR LLC, along with Abigail P. Johnson, has filed a Schedule 13G indicating their beneficial ownership of Arrowhead Pharmaceuticals Inc. common stock.
• As of March 31, 2026, the total beneficial ownership reported is 7,349,106.75 shares, representing 5.2% of the class of securities.
• FMR LLC holds sole voting power for 7,323,647.12 shares and sole dispositive power for 7,349,106.75 shares.
• Abigail P. Johnson is identified as a Director, Chairman, and CEO of FMR LLC, and members of the Johnson family are predominant owners of FMR LLC's voting shares.
• The filing indicates that while other persons may have the right to receive or direct dividends or proceeds from sales, no single other person's interest exceeds five percent of the total outstanding common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by a large investment firm and does not inherently signal positive or negative performance for the underlying company.

Positives

• FMR LLC and Abigail P. Johnson have disclosed a significant ownership stake of 5.2% in Arrowhead Pharmaceuticals Inc., indicating confidence or investment interest.
• The reporting is conducted in accordance with SEC regulations, ensuring transparency for investors.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control.

Risks

• The filing does not contain specific forward-looking statements or risk factors related to Arrowhead Pharmaceuticals Inc.'s business operations, as it is a Schedule 13G disclosure of beneficial ownership.
• Potential future changes in FMR LLC's ownership stake could impact Arrowhead Pharmaceuticals Inc.'s stock.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain specific forward-looking statements or guidance from Arrowhead Pharmaceuticals Inc.

Management Comments

• Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC.
• Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC.
• The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares.
• Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by FMR LLC, a major investment management firm, signifies a substantial institutional investment in Arrowhead Pharmaceuticals Inc., a company operating in the biotechnology sector, which is often characterized by significant research and development activities and potential for high growth or volatility.

Corporate Governance

Stakeholder Impact

• Shareholders of Arrowhead Pharmaceuticals Inc.: The disclosure provides transparency regarding a significant institutional investor's stake, which can influence market perception and trading activity.
• FMR LLC Shareholders: The filing indirectly relates to the management and governance of FMR LLC, with Johnson family members holding significant control and voting power.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to hold their beneficial ownership in Arrowhead Pharmaceuticals Inc. unless they decide to change their stake.
• Arrowhead Pharmaceuticals Inc. will continue its operations and disclosures as per its business cycle and regulatory requirements.

Key Dates

Keywords

Arrowhead Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, SEC Filing, Investment, Common Stock, Fidelity